Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 1 IntelGen x Technologies, Corp. November 2007 We make approved drugs better We make approved drugs better

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 2 Who we are Patents 3 issued, 7 pending 10 drugs Large Markets Addressing unmet needs: Erectile Dysfunction US$2b Osteoarthritis – US$10b Neuropathic Pain – US$10b Depression – US$15b Smoking Cessation – US$1b Partnerships Schwarz Pharma Azur Pharma Cannasat Therapeutics Cary Pharmaceuticals Technologies Oral Film Versatab Layered Tablets

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 3 Who Are We - Financial Overview Founded: 2003 Listed July 2006 OTCBB: IGXT Recent price:$1.75 Share Volume (avg):50k/day Cash/Equivalent:$1m Debt – Long-term:None Burn rate (qtrly):~$300k Market Capitalization:~$30m –Shares fully diluted:17m Insider ownership:67% We make approved drugs better We make approved drugs better

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 4 Management Team Horst G. Zerbe, Ph.D., CEOholds 40 patents, 27 yrs of industry experience with Schwarz Pharma, 3M Pharmaceutical, as VP of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ, and most recently as president of Smartrix Technologies Inc. Gino Di Iorio, CA, CFOExtensive experience in financial analysis, accounting, and regulatory filings. Prior companies include Viropro Inc., Draft inc., Sitel Corp. James Wittenberg, R.Ph, MS, Vice President, Bus. Dev.>20 years of experience in the pharmaceutical industry in market research and business development, most recently as Director of Business Development at Schwarz Pharma and Boots.

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 5 Pharmaceutical Industry Facing Challenges Increase in Generics Fewer new drugs coming to market Market share of generics and % growthNumber of New Drugs Approved in the U.S. Pharmaceutical Industry US$650b growing at 5-7% Industry growth slowing because of increased generics and fewer product launches Source: IMS Source: FDA

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 6 Drug Delivery Industry Growing Faster Than Rest Of Industry Drug Delivery Industry US$60b growing at 15% Controlled release drugs, improved drugs or “Ultra drugs” to extend product life cycle of successful branded drugs after patent expiration using 505(b)(2) approach Source: IMS

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 7 IntelGenx - Product Pipeline Prenatal Vitamin Antidepressant Osteoarthritis Smoking Cessation Neuropathic Pain Antihypertensive Erectile Dysfunction Preclinical Development Pilot BE Study Mfg. Scale-Up Pivotal BE Study Commercial Launch Platform Tablet Oral Film Partnered drugs H1/08 H2/08 H1/10 H2/09 H2/10 n/a

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 8 Oral Film Market – New Opportunities  Huge success in OTC products – Anti-histamines – Anti-flatulence – Anti-diarrhea – Anti-emesis – Cough/cold products  Advantages of Oral Film products – Reduce problems in swallowing – Instant release of drugs – Lower dose of drug required – Targeting children and elderly patients – Patient compliance

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB 9 Quick Release Oral Strips Onset of action and plasma concentration after administration of wafer and conventional tablet Advantages Instant release of drugs Avoids hepatic inactivation (first-pass effect) FDA approved for pharmaceutical products Improved patient compliance Adjustable flavours and textures Patented technology

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Oral Strips – Erectile Dysfunction Indication: Erectile Dysfunction 2006 global sales (US$): $2.0b Partner: Internal project Current status:Formulation development ongoing Expected commercialization: 2009 Patent Status:Expiry 2023 Rationale User friendly Easier to take Rapid onset of action

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Versatab Multilayer Tablet Platform Advantages High drug loading capacity (important for once- daily formulations) Ability to co-release multiple drugs with different release rates Suitable for large number of actives Highly versatile, broad range of delivery profiles Manufacturing cost savings of 50% compared to other oral delivery technologies Erodible Cover Active Matrix Matrix

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Versatab Multi-Layered Tablets – Novel Antidepressant Indication: Severe Depressive Disorder 2006 global sales (US$): > $1 b Partner: Joint Venture with Cary Pharma Current status:Pilot Phase I Study Completed Expected commercialization: 2009 Patent Status:US application under review Rationale Uniquely positioned for target indication Source: Company reports

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Need for Combination Products Combination drugs taking a leadership role to create a strategic advantage against generics +15% Source: IMS

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Versatab Multi-Layered Tablets – Bupropion HCL + Mecamylamine HCL Indication: Smoking Cessation 2006 global sales (US$): > $1 b Partner: Cary Pharma Current status:Phase I ongoing Expected commercialization: 2009 Patent Status:US application pending, use patent issued Rationale May have fewer side effects Dual mechanism of action Source: Company reports

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Active drugs: NSAID + Gastroprotectant Platform:Multilayer Tablet Indication: Osteoarthritis 2005 global sales (US$): 12 bn total OA market 2006 projected:500 million Partner: US Company S. Current status:Formulation development completed Expected commercialization: 2009 Patent Status:US and PCT applications pending Versatab Multi-Layered Tablets – INT005/05 Status: Total OA market > US$12 bn  Growing at +12%  Strong growth due to withdrawal of COX-2 inhibitors

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Versatab Multi-Layered Tablets – Metropolol Succinate Indication: Hypertension 2006 global sales (US$): $1.7b Partner: Internal project Current status:Manufacturing Scale-up ongoing Expected commercialization: 2008 Patent Status:US application pending Rationale Lower cost alternative to branded drug Source: Company reports

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Versatab- In Vivo Performance Plasma concentrations of Metoprolol Succinate IntelGenx trilayer tablets vs Toprol XL tablets (single dose, fasted, n=6)

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Competitive Landscape – Drug Delivery CompanyTabletsOral Films # Products in Development Market Cap US$m Penwest PPCO-N YesNo11$300 Depomed – DEPO-N YesNo6$100 Labopharm- DDS-T YesNo2$110 Emisphere – EMIS-N YesNo10$120 IntelGenx- IGXT-OTCBB Yes 10$30

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB Revenue Projection

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB IntelGenx - Delivering Value Reasons to Invest Strong management and key scientific expertise Broad product pipeline – 10 drugs addressing a total US$20 billion markets Unique, proprietary drug delivery platform technologies Multiple Partnerships - 4 drugs in development Clinical Development in progress for 4 products Near-term revenue expectations - Prenatal Vitamin Attractive valuation

Innovative Drug Delivery Solutions Innovative Drug Delivery Solutions IGXT-OTCBB IGXT-OTCBB IntelGen x Technologies, Corp. November 2007 Thank You IntelGen x Thanks you very much for your time and attention.